5. Kenneth Frazier CEO, Merck
It’s easy to forget that last August, after President Trump’s tepid response to a white nationalist rally that turned violent, outcry from the business community was not immediate. Frazier took a risk by becoming the first of Trump’s advisers to speak out and step down, enabling others to follow suit.
Ver:
Frazier Vs Trump: Frazier's call earns him praise, rare for a pharma CEO / Y Gorsky también renuncia.
USA: Most Investors Respect The Merck CEO’s Decision To Resign From Trump’s Council
Kenneth C. Frazier (Ceo Merck) renuncia a la Presidencia de American Manufacturing Council
His success at Merck only bolsters his credibility: Since he took over in 2011, the pharma giant has made strides in treating several cancers, while its stock beat the S&P 500.
It’s hard to imagine a federal agency that touches more of our lives—and in more personal ways—than the Food and Drug Administration. It reaches in through our medicine cabinets, regulating everything from our morning pills to makeup—and through our kitchen cupboards, ensuring the safety of most of what we ingest each day, even bottled water. Its purview extends from pet food to microwave ovens to vaccines, pacemakers, and bedpans. And in the year since he has been FDA commissioner, Scott Gottlieb has appeared to have had a direct hand in all of it.
"In Gottlieb and HHS Director Alex Azar,
a former Eli Lilly executive,
the pharma industry has allies in Trump's administration.
It remains to
be seen just how the administration
will try to fulfill its promise on
drug prices,
but early reports indicate
it'll be through tactics
proposed by Gottlieb,
plus value-based pricing
Ver:
FDA: Trump apostó por O’Neill pero se decidió por Gottlieb
Seven pharma trends for 2018
Gottlieb, a physician and former VC who served as a deputy commissioner in the administration of President George W. Bush, has earned broad kudos from a constituency that is often beset by bitter argument. He has pushed for creative ways to slow the skyrocketing rise of medicine prices (in part by making it easier for generics to compete), helped speed the development of digital health technologies through clearer regulatory guidance, embraced more efficient clinical trial designs, and aggressively tried to reduce cigarette smoking and contain America’s raging opioid epidemic through sharp policy moves.
An avid (perhaps even obsessive) tweeter, Gottlieb @ScottGottliebMD has gotten credit for being transparent about FDA steps—and, more important, for using his bully pulpit without being a bully.
Más
Entradas
No hay comentarios:
Publicar un comentario